Irinotecan Combination Chemotherapy for Refractory or Relapsed Brain Tumor in Children and Adolescents

NCT01535183 | Unknown Phase 2

• 1 other identifier: SNUCH-1201
• Study Type: interventional
• Target: 40
• Locations: 1 country
• Sites: 1

Brief Summary

The outcome of pediatric refractory or relapsed brain tumor is very dismal. Standard chemotherapy showed poor response to these patients. Although tandem high dose chemotherapy with hematopoietic progenitor stem cell rescues has been chosen as a potentially curative therapy for long term survival and better outcome is expected if tumor burden before transplantation reduced by chemotherapy, effective salvage chemotherapy for tumor reduction is not established yet. Irinotecan is a recently developed topoisomerase I inhibitor, and there are preclinical and phase I, II data which proved practical effects in brain tumors. In those studies, irinotecan was administered alone or in combination with one other drug. Vincristine, etoposide, carboplatin, and cyclophosphamide have been used in many protocols for brain tumors but the result was very poor in refractory or relapsed cases. However, irinotecan can be effective with these multiple chemotherapeutic agents. According to the pilot study of irinotecan in combination with vincristine, etoposide, carboplatin and cyclophosphamide in the investigators center, 75% percent of total 12 patients reached more than stable disease, and 2 patients got long term complete remission only with this multi-agent combination chemotherapy. But the combination of irinotecan, vincristine, etoposide, carboplatin, and cyclophosphamide is not clinically studied yet especially for pediatric patients. To improve response rate and progression-free survival, the combination chemotherapy of irinotecan, vincristine, etoposide, carboplatin, and cyclophosphamide is designed for pediatric refractory or relapsed brain tumor.

Conditions

Brain Tumor

Keywords

irinotecan; brain tumor; pediatrics; salvage therapy; chemotherapy

Outcome Measures

Primary Outcomes (1)

• To evaluate response rate (more than stable disease) of combination chemotherapy

  \- Response Criteria : WHO-based "Macdonald criteria", based on MRI 1. Complete Response : disappearance of all enhancing tumor 2. Partial Remission : more than 50 percentage decrease in the tumor measurement compared with the baseline scan 3. Stable Disease : includes changes that do not meet criteria for CR, PR, or progressive disease (PD) 4. Progressive Disease : more than 25 percentage increase in tumor measurement compared with the lesion size that defines the nadir, or smallest measurement, in the serial studies

  every 3 months

Secondary Outcomes (2)

• To evaluate adverse event

  during chemotherapy and every follow up (3 times a week, up to 4 weeks)

• To evaluate progression-free survival

  until last follow up (at least 1year)

Study Arms (1)

Irinotecan

EXPERIMENTAL

Drug: Irinotecan combination chemotherapy

Interventions

Irinotecan combination chemotherapy DRUG

Irrinotecan 300㎎/㎡ d0 IVS mixed with D5W 500mL over 90min with atropine (-30 min) VCR 2㎎/㎡ d0 IV push Etoposide 100㎎/㎡ d0-d2 IV over 1hr Carboplatin 450㎎/㎡ d0 IV over 8hrs Cyclophosphamide 1,000㎎/㎡ d1 IVS with mesna

Also known as: Camptosar (Pfizer) or Campto (Yakult Honsha)

Irinotecan

Eligibility Criteria

• Age: Up to 19 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64)

You may qualify if:

• Diagnosis of brain tumor : embryonal brain tumor (medulloblastoma, CNS PNET, ATRT, etc), intracranial germ cell tumor
• Relapse or refractory state
• Prior therapy : Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study. Patients are eligible 8 weeks from the day of stem cell infusion for autologous stem cell transplant, if hematological and all other eligibility criteria are met.
• Performance status: ECOG 0-2.
• Patients must be free of significant functional deficits in major organs, but the following eligibility criteria may be modified in individual cases.
• Heart: a shortening fraction ≥ 28%
• Liver: total bilirubin \< 2 × upper limit of normal; ALT \< 3 × upper limit of normal.
• Kidney: creatinine \<2 × normal
• Patients must lack any active viral infections or active fungal infection.
• Patients (or one of parents if patients age \< 20) should sign informed consent.

You may not qualify if:

• Pregnant or nursing women.
• Malignant (except brain tumor) or nonmalignant illness that is uncontrolled or whose control may be jeopardized by complications of study therapy.
• Psychiatric disorder that would preclude compliance.
• Patients who, in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study.

Sponsors & Collaborators

• Seoul National University Hospital: lead

Study Sites (1)

Seoul National University Hospital

Seoul, Chongno-gu, 110-744, South Korea

RECRUITING

MeSH Terms

Conditions

Brain Neoplasms

Interventions

Irinotecan

Condition Hierarchy (Ancestors)

Central Nervous System Neoplasms; Nervous System Neoplasms; Neoplasms by Site; Neoplasms; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases

Intervention Hierarchy (Ancestors)

Camptothecin; Alkaloids; Heterocyclic Compounds

Study Officials

• Hyoung Jin Kang, M.D., ph.D

  Seoul National University Hospital

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 7, 2012
• First Posted: February 17, 2012
• Study Start: January 1, 2012
• Primary Completion: September 1, 2016
• Study Completion: December 1, 2016
• Last Updated: July 14, 2014

Record last verified: 2014-07

Locations

KR (1)